1,000,000,000 (YES BILLION) shares shorted since 1st $BMSN! otcshortreport.com/BMSN It's going to be BRUTAL here next week for those that shorted . Wow no wonder $BMSN is on the SHO list http://www.nasdaqtrader.com/Trader.aspx?id=RegSHOThreshold Whoever made such a poor investment decision as that better ask for their money back LOL! OOPS, TOO LATE! I say we're flying past pennies. We might be talking about 10 cents and above. I see now why all the AMB* comparisons were made.
SHORT SQUEEZE, short squeeze! Step right up, and get your short squeeze!
#1 On Friday January 25th, 2013 $BMSN was announced to be on NASDAQ's regulatory SHO list as an officially shorted stock where significant short positions had failed to deliver shares for an overextended period of time http://www.nasdaqtrader.com/Trader.aspx?id=RegSHOThreshold This tells us a massive amount of shares have been shorted and if those shares are not covered within the next couple days there will be SEVERE and IMMEDIATE financial obligations which the brokerage houses holding those accounts will be forced to pay. Have you ever heard of a brokerage house paying your bills on a bad trade--nope. Therefore these shares MUST be covered within the next couple days which will cause a significant surge in share price. #2 On Saturday January 26th, 2013 http://otcshortreport.com , a very popular short report website listed $BMSN as being shorted by over 1 BILLION SHARES.. yes 1,000,000,000 since January 1st http://otcshortreport.com/bmsn #3 Just yesterday, on Sunday January 27th, 2013 news had spread to ihub that BTNSR, a subsidiary run off of Sierra World Equity Review announced a Price Target of $1.55 for $BMSN's IND by the summer time just a day before http://biotechnewsstockreview.blogspot.com/2013/01/bio-matrix-scientific-group-bmsn-price.html
--------------------------------------------
Saturday, January 26, 2013 Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review. Adam feels that BMSN could quite possible become the stock of the year. Look for an epic run to begin after the filing of the IND and not stop until summer when the share price will hit $1.55. Lots of people are going to get rich off the back of BMSN.
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was fundamental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing. Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts. If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about. Posted by Sierra World Equity Review at 10:44 PM
--------------------------------------------
In conclusion with a pending short squeeze, IND, and news/financials to be released by end of this week we are looking at a MASSIVE increase in share price to take place. This will last into the next 3-4 months with many ups and downs but a consistent uptrend at least to $0.50 A measly $2,000 investment at .003 will become $333,333 at .50
--------------------------------------------
OS SHARES LAST FILED AS OF OCT 23,2012 OUTSTANDING 323M
REGEN BIOPHARMA, INC. A Bio-Matrix wholly owned subsidiary,
Regen BioPharma has assessed over 20,000 stem cell related issued patents, narrowed down to 2000 patents with commercial applicability, and further identified 30 patents available for licensing. The company seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies.
WHY STEM CELL TRANPLANTS ARE UNSUCCESSFUL...STEM CELLS DIE AFTER A WEEK. Method for enhancing hematopoiesis Patent #6,821,513
--------------------------------------------
What will you be doing with your massive gains? Write me back or PM me. I will most likely be taking a long vacation to Jamaica/Brazil/Switzerland/Caribbean Cruise And don't forget to follow me http://investorshub.advfn.com/boards/profilea.aspx?user=373707
--------------------------------------------
(EOM)
See my other previous posts on $BMSN as well here:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
. Wow no wonder $BMSN is on the SHO list http://www.nasdaqtrader.com/Trader.aspx?id=RegSHOThreshold Whoever made such a poor investment decision as that better ask for their money back LOL! OOPS, TOO LATE! I say we're flying past pennies. We might be talking about 10 cents and above. I see now why all the AMB* comparisons were made. 
